Jane Larkindale
Corporate Officer/Principal at PEPGEN INC.
Network origin in Jane Larkindale first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
13
| Public Company | Biotechnology | 13 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Jane Larkindale via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| AEROVATE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chairman | |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal | |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Pharmaceuticals: Major | Director of Finance/CFO | |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor | |
Nayan Therapeutics, Inc.
 Nayan Therapeutics, Inc. BiotechnologyHealth Technology Nayan Therapeutics, Inc. operates as a biotechnology company. It focuses on small molecule development for oscular disorders involving rod degeneration. The company is headquartered in Medfield, MA. | Biotechnology | Director/Board Member | |
Ventus Therapeutics, Inc.
 Ventus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ventus Therapeutics, Inc. operates as a biopharmaceutical company. It focuses in developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases and cancer. The company was founded by Hao Wu, Richard Flavell, Judy Lieberman, Thomas Tuschl, and Feng Shao and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member | |
Be Biopharma, Inc.
 Be Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Be Biopharma, Inc. develops engineered B cells as a new category of cellular medicines. The company was founded by David Steinberg, Aleks Radovic-Moreno and Lea Hachigian and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
New England Venture Capital Association, Inc.
 New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Medical/Nursing Services | Director/Board Member | |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Santi Therapeutics, Inc.
 Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
| VOR BIOPHARMA INC. | Biotechnology | Director/Board Member | |
Caraway Therapeutics, Inc.
 Caraway Therapeutics, Inc. BiotechnologyHealth Technology Caraway Therapeutics, Inc. provides heathcare services. The company was founded by Timothy Harris, Wade Harper ,Ivan Dikic ,Tony Hyman and is headquartered in Cambridge, MA. | Biotechnology | President | |
Ventus Therapeutics U.S., Inc.
 Ventus Therapeutics U.S., Inc. Medical DistributorsDistribution Services Ventus Therapeutics U.S., Inc. operates as a biotechnology company. The company is headquartered in Natick, MA. | Medical Distributors | Director/Board Member | |
| AVROBIO, INC. | Biotechnology | Director/Board Member | |
| KALVISTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
SV Health Investors LLC
 SV Health Investors LLC Investment ManagersFinance SV Health Investors LLC is a Venture Capital firm, a subsidiary of SV Health Investors LLP founded in 2006. SV Health Investors LLC is headquartered in Boston. | Investment Managers | Private Equity Investor | |
| ALECTOR, INC. | Biotechnology | Director/Board Member | |
| TRANSLATE BIO, INC. | Biotechnology | Director/Board Member | |
| SPERO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
| University of Pennsylvania School of Dental Medicine | College/University | Doctorate Degree | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
Bright Peak Therapeutics, Inc.
 Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | Pharmaceuticals: Major | Director/Board Member | |
| VISTERRA INC | Pharmaceuticals: Major | Director/Board Member | |
| AVEDRO, INC. | Medical Specialties | Director/Board Member | |
| Babson College | College/University | Masters Business Admin | |
| Boston University | College/University | Graduate Degree | |
| University of Vermont | College/University | Undergraduate Degree | |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. | College/University | Graduate Degree | |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| DICERNA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Colgate University | College/University | Undergraduate Degree | |
| Wake Forest University | College/University | Doctorate Degree | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| FULCRUM THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Southern Denmark | College/University | Doctorate Degree | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ASCENDIS PHARMA A/S | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistics
International
| United States | 44 |
| Denmark | 4 |
| Canada | 2 |
| Switzerland | 2 |
| United Kingdom | 2 |
Sectoral
| Health Technology | 33 |
| Consumer Services | 10 |
| Finance | 4 |
| Commercial Services | 4 |
| Health Services | 3 |
Operational
| Director/Board Member | 64 |
| Corporate Officer/Principal | 25 |
| Independent Dir/Board Member | 22 |
| Director of Finance/CFO | 12 |
| Chief Tech/Sci/R&D Officer | 11 |
Most connected contacts
| Insiders | |
|---|---|
| Joshua Resnick | 36 |
| Heidi Henson | 20 |
| Howard Mayer | 16 |
| James McArthur | 15 |
| Laurie Keating | 13 |
| Christopher Ashton | 12 |
| Habib Dable | 11 |
| Mary DeLena | 6 |
| Michelle Mellion | 6 |
| Niels Svenstrup | 5 |
| Jeffrey Foy | 5 |
| Noel Donnelly | 4 |
| Isami Salcedo | 3 |
- Stock Market
- Insiders
- Jane Larkindale
- Company connections
